As Alzheimer’s clinical trials continue to evolve, this webinar highlights the latest advances in real-world longitudinal data collection, featuring key findings from a first-in-class study (CNS-101) presented at the recent Alzheimer’s Association International Conference (AAIC).
CNS-101 was designed and executed in collaboration with 10 top pharma companies utilizing a platform that combines at-home multimodal assessments, passive EEG and naturalistic language markers to track Alzheimer’s disease progression. The study demonstrated that repeated, at-home measurements provide greater sensitivity and statistical power than the widely used Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 13), enabling more accurate and scalable monitoring of dementia progression. Additionally, the study confirmed that at-home endpoints associated with Alzheimer’s pathology (phosphorylated tau 217) outperformed traditional benchmark measures over time.
Digital endpoints address the key limitations associated with “snapshot in time” clinic-only measures by enabling longitudinal, real-world monitoring that accurately reflects patient disease trajectory and cognitive performance in day-to-day life, where it matters the most.
The featured speakers will explore strategies for improving clinical trial designs for Alzheimer’s disease, emphasizing the integration of digital biomarkers to enhance sensitivity, objectivity, scalability and patient-centricity. They will discuss how digital endpoints collected in clinics and at home can provide greater discriminative power than standard measurement tools used in CNS clinical studies today. Importantly, they will discuss how these findings can be translated across a broad range of CNS disease states.
This webinar aims to illustrate how the evolution of remote, real-world data collection can enable leaner trial designs, accelerate clinical development of effective CNS therapies and ultimately improve the lives of millions of patients affected by Alzheimer’s disease.
Register for this webinar to learn how digital endpoints are transforming Alzheimer’s disease clinical trials.
- Alzheimer's Disease ,
- At Home Monitoring ,
- At-Home Test ,
- Biomarkers ,
- Clinical Data ,
- Clinical Research ,
- Clinical Trial Design ,
- Clinical Trial Endpoints ,
- Clinical Trials ,
- CNS ,
- CNS Trials ,
- CRO ,
- Digital Biomarkers ,
- Digital Endpoints ,
- Drug Development ,
- EEG ,
- Endpoints ,
- Neurological Disease ,
- Neurological Disorder ,
- Neurology ,
- Real Time Data ,
- Real-World Data
Speakers
Brian Murphy, PhD, Co-Founder and CSO, Cumulus Neuroscience
Dr. Brian Murphy is the Co-Founder and Chief Scientific Officer at Cumulus Neuroscience. He is a computational neuroscientist and expert in brain-reading technology using machine learning methods to decode cognitive states from recordings of brain activity (EEG, fMRI, MEG) and other data. His academic career included positions as assistant professor in Data Science at Queen’s University Belfast, as senior researcher at Carnegie Mellon University’s Department of Machine learning, the world’s leading lab for applying machine learning to brain activity, and as post-doc at the Centre for Mind/Brain Sciences, University of Trento, Italy, one of Europe’s leading cognitive neuroscience centres.
He has a PhD in Cognitive Science from Trinity College Dublin and prior to academia, worked in and co-founded web startups in Germany and China. Brian is a member of the Alzheimer’s Association EEG PIA committee, and organised the MLINI series of workshops on machine learning with neuroimaging data at NeurIPS, the world’s leading machine learning conference.
Message Presenter
Dr. Ruth McKernan, FMEdSci CBE, Operating Partner, SV HealthInvestors; CEO, Draig Therapeutics; Chair, Cumulus Neuroscience
Dr. Ruth McKernan is a Neuroscientist and biotech leader with a career spanning academia, industry and government. She led Neuroscience at Merck and later served as CSO at Pfizer’s Neusentis unit. From 2015 to 2018, she was the CEO of Innovate UK. She is a founding director of Astronautx, a venture partner at the Dementia Discovery Fund and Chair of the UK BioIndustry Association. McKernan holds a PhD in Pharmacology from King’s College London and is a Fulbright Scholar.
Dr. Ruth McKernan is an Operating Partner at SV HealthInvestors and CEO of Draig Therapeutics, as well as Chair of Cumulus Neuroscience.
Message Presenter
Bryan J. Hansen, PhD, Pharma Neuroscientist, Technologist, and Innovator
Dr. Bryan J. Hansen is an accomplished leader in neuroscience, digital health, and clinical research, with expertise in neurodegeneration and neuropsychiatric disorders. He holds a PhD in Systems Neuroscience and has directed research studies that investigate complex EEG-based biomarkers in both academic and industry settings. Dr. Hansen has built a career promoting clinical innovation and shaping strategy across therapeutic areas. He is passionate about forging strategic partnerships and turning complex data into actionable insights that accelerate clinical development and improve patient outcomes.
Currently, Dr. Hansen is working across the industry with sponsors, academics, and companies, driving innovation at the intersection of neuroscience, data science, and digital health.
Message Presenter
Professor James Rowe, BA BMBCh FRCP PhD, Director of Cambridge Centre for Frontotemporal Dementia and Related Disorders, in the Department of Clinical Neurosciences, University of Cambridge
Professor James Rowe is a Professor of Cognitive Neurology at the University of Cambridge and is also a Consultant Neurologist at Cambridge University Hospitals. He leads clinics in dementia and related disorders and directs the Cambridge Centre for Frontotemporal Dementia. A Wellcome Trust Senior Research Fellow, Rowe has published over 560 papers on cognitive ageing and neurodegeneration. He earned his Medical and Doctoral degrees from Cambridge, Oxford, and UCL with training in Neuroimaging and Neurology.
Message PresenterWho Should Attend?
This webinar will appeal to professionals focused on diseases in the CNS space in the following fields:
- Biopharma clinical operations
- Clinical R&D
- Medical affairs
What You Will Learn
Attendees will:
- Hear from CNS thought-leaders on the transformative power of at-home and in-clinic innovations in CNS clinical trials
- Learn how digital biomarkers have the potential to transform CNS clinical trials much the same way that next-generation sequencing has transformed oncology, enabling personalized treatment
- Gain insight into the power of longitudinal EEG data synchronized with behavioral assessment data, and how this can enable leaner trial designs and accelerate clinical development of CNS therapies
Xtalks Partner
Cumulus Neuroscience
With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing NeuLogiq®, an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world’s leading pharma companies, the platform enables decentralized trials, and is already making a difference in the development of therapies for Alzheimer’s Disease, depression and schizophrenia.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account